These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
220 related articles for article (PubMed ID: 6752559)
1. The antihypertensive effect of captopril in severe essential, renovascular, renal and transplant renovascular hypertension. Schwietzer G; Oelkers W Klin Wochenschr; 1982 Aug; 60(16):839-46. PubMed ID: 6752559 [TBL] [Abstract][Full Text] [Related]
2. Sustained antihypertensive effect of captopril combined with diuretics and beta-adrenergic blocking drugs in patients with resistant hypertension. Forslund T; Fyhrquist F; Hortling L Acta Med Scand; 1983; 213(4):299-303. PubMed ID: 6137132 [TBL] [Abstract][Full Text] [Related]
3. Hemodynamic and antihypertensive effects of captopril, an orally active angiotensin converting enzyme inhibitor. Sullivan JM; Ginsburg BA; Ratts TE; Johnson JG; Barton BR; Kraus DH; McKinstry DN; Muirhead EE Hypertension; 1979; 1(4):397-401. PubMed ID: 232084 [TBL] [Abstract][Full Text] [Related]
4. Captopril, an orally active angiotensin I converting enzyme inhibitor in the treatment of renovascular and essential hypertension. Holtzman E; Rosenthal T; Stern N; Knecht A; Yaron A Isr J Med Sci; 1982 May; 18(5):597-602. PubMed ID: 6284678 [TBL] [Abstract][Full Text] [Related]
5. [Usefulness of angiotensin converting enzyme inhibitors in the diagnosis of renovascular hypertension. II. Comparison of the effect of angiotensin converting enzyme inhibition on reno-scintigraphic curves with DTPA in patients with essential and renovascular hypertension]. Posadzy-Małaczyńska A Przegl Lek; 1997; 54(7-8):524-8. PubMed ID: 9480462 [TBL] [Abstract][Full Text] [Related]
6. Differentiation between renovascular and essential hypertension by means of changes in single kidney 99mTc-DTPA clearance induced by angiotensin-converting enzyme inhibition. Pedersen EB; Jensen FT; Eiskjaer H; Hansen HH; Jensen JD; Jespersen B; Madsen B; Nielsen HK; Sørensen SS Am J Hypertens; 1989 May; 2(5 Pt 1):323-34. PubMed ID: 2655658 [TBL] [Abstract][Full Text] [Related]
7. Captopril in treatment-resistant essential and renal hypertension. Aurell M; Delin K; Herlitz H Scand J Urol Nephrol; 1982; 16(3):243-9. PubMed ID: 6761860 [TBL] [Abstract][Full Text] [Related]
8. A discrepancy between the effects of a single oral dose of captopril on blood pressure, plasma renin activity, and serum angiotensin-converting enzyme levels. Lechi A; Covi G; Capuzzo MG; Lechi C; Minuz P; Delva P; Scuro LA Int J Clin Pharmacol Ther Toxicol; 1983 Nov; 21(11):569-74. PubMed ID: 6317579 [TBL] [Abstract][Full Text] [Related]
9. Clinical experience with captopril in the treatment of severe drug-resistant hypertension. Raine AE; Ledingham JG Am J Cardiol; 1982 Apr; 49(6):1475-9. PubMed ID: 7041586 [TBL] [Abstract][Full Text] [Related]
10. Antihypertensive effects of captopril and saralasin in essential and renal hypertension. Konrads A; Meurer KA; Hummerich W; Wambach G; Kindler J; Feltkamp H; Helber A Am J Cardiol; 1982 Apr; 49(6):1558-60. PubMed ID: 7041597 [TBL] [Abstract][Full Text] [Related]
11. [Usefulness of converting enzyme inhibitors in diagnosis of renovascular hypertension. I. Comparison of the effect of angiotensin converting enzyme inhibition on blood pressure and plasma renin activity in patients with primary hypertension and renovascular hypertension]. Posadzy-Małaczyńska A Przegl Lek; 1997; 54(5):314-9. PubMed ID: 9380805 [TBL] [Abstract][Full Text] [Related]
12. [Evaluation of the acute effect of a converting enzyme inhibitor, captopril, in normal and hypertensive subjects]. Mimran A; Laroche B; Targhetta R; Roumieux JL Arch Mal Coeur Vaiss; 1981 Jun; 74 Spec No():61-5. PubMed ID: 6794529 [TBL] [Abstract][Full Text] [Related]
13. Long-term efficacy of captopril in renovascular and essential hypertension. Case DB; Atlas SA; Marion RM; Laragh JH Am J Cardiol; 1982 Apr; 49(6):1440-6. PubMed ID: 6803561 [TBL] [Abstract][Full Text] [Related]
14. Long-term effect of captopril on kidney function in various forms of hypertension. Vetter W; Wehling M; Foerster EC; Kuhlmann U; Boerlin HJ; Greminger P; Vetter H Klin Wochenschr; 1984 Aug; 62(15):731-7. PubMed ID: 6387263 [TBL] [Abstract][Full Text] [Related]
15. Effects of captopril on renal function in hypertensive patients. Pessina AC; Semplicini A; Rossi G; Gatta A; Palatini P; Gava R; Casiglia E; Dal Palú C Am J Cardiol; 1982 Apr; 49(6):1572-3. PubMed ID: 7041601 [TBL] [Abstract][Full Text] [Related]
16. Effects of the angiotensin converting enzyme inhibitors captopril, rentiapril, and alacepril in patients with essential and renovascular hypertension. Ideishi M; Sasaguri M; Ikeda M; Arakawa K Clin Ther; 1989; 11(4):441-51. PubMed ID: 2550133 [TBL] [Abstract][Full Text] [Related]
17. Effect of captopril on blood pressure and renal function in patients with transplant renal artery stenosis. van der Woude FJ; van Son WJ; Tegzess AM; Donker AJ; Slooff MJ; van der Slikke LB; Hoorntje SJ Nephron; 1985; 39(3):184-8. PubMed ID: 2983251 [TBL] [Abstract][Full Text] [Related]
18. Clinical evaluation of the captopril screening test for primary aldosteronism. Naomi S; Iwaoka T; Umeda T; Inoue J; Hamasaki S; Miura F; Fujii Y; Sato T Jpn Heart J; 1985 Jul; 26(4):549-56. PubMed ID: 3903249 [TBL] [Abstract][Full Text] [Related]
19. Effects of angiotensin I converting enzyme inhibitor (SQ 14,225) on the responses of blood pressure and steroid hormone to angiotensin II and ACTH infusion in hypertensive subjects. Ueda Y; Honda M; Hatano M Jpn Circ J; 1982 Mar; 46(3):267-73. PubMed ID: 6278173 [TBL] [Abstract][Full Text] [Related]
20. Renal hemodynamics in essential and renovascular hypertension. Influence of captopril. Hollenberg NK Am J Med; 1984 May; 76(5B):22-8. PubMed ID: 6328983 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]